Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

196
UNKNOWN
G.I. and Other Associated Cancers Research Group

Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics compared to CA19-9 alone.

Specific Aim 1) Utilize newly developed and to be developed antibodies against the mucin core proteins MUC1, MUC4, and MUC17 to develop an improved serum assay for pancreatic adenocarcinoma. Specific Aim 2) Develop and utilize a set of monoclonal antibodies that recognize serum forms of distinct mucin core proteins, utilize these to improve the diagnostic capability of the CA 19-9 type tests for nonmalignant, premalignant and malignant lesions of the pancreas, and evaluate the capability of the test to discriminate pancreatic cancer from other adenocarcinomas.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.